Pharmaceuticals company Bajaj Healthcare announced Q3FY25 results Revenue: Rs 1,227.9 million compared to Rs 1,085.7 million during Q3FY24, change 13.1%. EBITDA: Rs 240.1 million compared to Rs 203.3 million during Q3FY24, change 18.1%. EBITDA margin: 19.6% for Q3FY25. PAT: Rs 117.2 million compared to Rs -219.6 million during Q3FY24, change 153.4%. PAT margin: 9.5% for Q3FY25. Anil Jain, Managing Director, said: “We are pleased to report yet another strong quarter of growth and profitability. Our PAT from continuing operations surged 171% YoY, driven by our relentless focus on operational excellence and cost efficiencies. At the same time, we remain committed to monetizing assets from discontinued operations, ensuring optimal capital allocation towards debt repayment and minimizing associated losses. Notably, our formulations segment saw a significant growth, with an impressive 58% YoY increase for the quarter. This rise in formulations revenue highlights the strength of our manufacturing expertise, as we continue to expand our portfolio and enhance our capabilities to meet market demand across key therapeutic areas. Our opium processing segment saw a 32% YoY growth and we remain optimistic about the long-term prospects of the alkaloid processing segment. Beyond financials, we reached significant milestones strengthening our market position. A key achievement was receiving approval from the Drug Controller General of India (DCGI) to manufacture both the API and formulation of Pimavanserin, solidifying our foothold in the central nervous system (CNS) segment. Pimavanserin, marketed globally as NUPLAZID®, has already gained significant traction in the US, and with Acadia Pharmaceuticals projecting combined net sales of over USD 1 billion in 2025 for NUPLAZID® and DAYBUE, we see a tremendous opportunity ahead. We are proud to expand our CDMO pipeline with a new contract for 15 APIs with UK/EU-based companies, reinforcing our global presence and expertise in cost-effective synthesis. This follows our earlier contract for 15 molecules this year. Additionally, the approval of our Gujarat API manufacturing site by the TGA, Australia, alongside USFDA and EU certifications, enables direct supplies to Australia and New Zealand, unlocking new global partnership opportunities. Looking ahead, we remain confident in our growth, driven by operational excellence, strategic partnerships, and innovation, as we work towards becoming a trusted global pharmaceutical partner.” Result PDF